13 July 2021 - trading update
The AIM-listed global pharmaceutical Products and Services company has released a trading update for the year ended 30 June 2021, ahead of the publication of final results on 16 September. Net revenue is expected to be £455m, representing an increase of 12% on a constant currency and organic basis. Including the contribution from the UK Specials and Aseptics compounding business, which was divested on 30 June 2021, reported net revenue is set to be £495m. Adjusted EBITDA is expected to be £116m, representing a fall of 10% on a reported basis and 6% on . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.